Loading
A phase 1/2 trial of Olaparib, Ipilimumab and Nivolumab in triple-negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Lantern Pharma Inc., active and no longer recruiting.
Study of LP-184 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05933265 by Lantern Pharma Inc., with 64 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2026-07-28. Interventions recorded: LP-184, Olaparib and Nivolumab & Ipilimumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lantern Pharma, Non-small-cell lung cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/